Conditions: Parkinson's Disease
Keywords: amyloid burden Parkinson's disease florbetapir PET amyloid PET imaging
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 31
Healthy volunteers: no

Brief summary:
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.

Detailed description:

Arms:
arm 1: Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance. arm 2: Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits. arm 3: Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.

Interventions: intervention 1: florbetapir F 18
Intervention descriptions: intervention 1: 10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection

Protocol document: